Treatment Outcome and Prognostic Factors for Pediatric Medulloblastoma Patients: The Egyptian National Cancer Institute Experience — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Treatment Outcome and Prognostic Factors for Pediatric Medulloblastoma Patients: The Egyptian National Cancer Institute Experience
Radiation Oncology and Nuclear Medicine Department, National Cancer Institute, Cairo University, Cairo, Egypt
,
Radiation Oncology and Nuclear Medicine Department, National Cancer Institute, Cairo University, Cairo, Egypt
,
Radiation Oncology and Nuclear Medicine Department, National Cancer Institute, Cairo University, Cairo, Egypt
1 Radiation Oncology and Nuclear Medicine Department, National Cancer Institute, Cairo University, Cairo, Egypt
2 Radiation Oncology and Nuclear Medicine Department, National Cancer Institute, Cairo University, Cairo, Egypt
3 Radiation Oncology and Nuclear Medicine Department, National Cancer Institute, Cairo University, Cairo, Egypt
Purpos e : To evaluate treatment outcomes and prognostic factors of pediatric Medulloblastoma (MB) patients treated by adjuvant post-operative riskadapted radiotherapy (RT) and chemotherapy (CT). Patients and Methods : A retrospective analysis was conducted based on medical records of pediatric patients with pathologically confirmed MB treated between 2006 and 2013 at the National cancer Institute (NCI), Egypt. Various patients’ and disease characteristics, treatment details and outcome data were reviewed. Results : Fifty patients’ records were included in the analysis with a median age of 6 years at diagnosis (range 3 - 18). According to the Chang staging system; 38%, 44%, 4%, and 14% were M0, M1, M2, and M3, respectively. All patients underwent primary surgery; gross total resection (with no residual) in 38%, near total resection (with residual ≤1.5 cm 2 ) in 8%, subtotal resection (with residual > 1.5 cm 2 ) in 34%, and 20% had only biopsy. All patients were treated by riskadapted craniospinal irradiation (CSI); high-risk patients were treated by CSI 36 Gy/20 fractions over 4 weeks followed by posterior fossa (PF) boost 18 Gy/10 fractions over 2 weeks (180 cGy per fraction), while standard-risk patients were treated by CSI 23.4 Gy/13 fractions over 2 and half weeks followed by PF boost 30.6 Gy/17 fractions over 3 and half weeks. Median overall treatment time (OTT) was 52 days. All patients received adjuvant CT; 47 patients (94%) received concomitant chemo radiotherapy (CCRT), while 4 patients (8%) only received neoadjuvant CT (NB: only one patient received all neoadjuvant, concomitant and adjuvant CT). With a median follow up time of 32.5 months, ranging from 6 to 104 months, the whole group estimates of the overall survival (OS) at 1, 3, and 5 years were 83%, 70%, and 64%, respectively, while, the progression-free survival (PFS) rates at 1, 3, and 5 years were 79%, 62%, and 57% respectively. Four patients relapsed. Neural-axis was the commonest site of relapse (3 patients). Both risk groups were equally represented in relapsed patients (2 standard risk & 2 high risk patients) and relapse took place within 2 years. In univariate analysis, performance status,extent of surgery, and post-operative residual tumor size were significant prognostic factors for OS. On the other hand, factors which affected the PFS included gender, extent of surgery, and post-operative residual tumor. Conclusion : Neural-axis relapse was the commonest site of relapse for pediatric MB patients. Extent of surgical resection, post-operative residual tumor, and gender are powerful prognostic factors. Maximal safe resection is the standard surgical approach for MB patients to achieve cure.
Mokhtar, N., Gouda, I. and Adel, I. (2007) Cancer Pathology Registry 2003-2004 and Time Trend Analysis. Department of Pathology, NCI.
Ellison, D.W., Clifford, S.C. and Gajjar, A. (2003) What’s New in Neuro-Oncology? Recent Advances in Medulloblastoma. European Journal of Paediatric Neurology, 7, 53-66.
Packer, R.J., et al. (2006) Phase III Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma. Journal of Clinical Oncology, 24, 4202-4208. https://doi.org/10.1200/JCO.2006.06.4980
Gajjar, A., et al. (2006) Risk-Adapted Craniospinal Radiotherapy Followed by High-Dose Chemotherapy and Stem-Cell Rescue in Children with Newly Diagnosed Medulloblastoma (St Jude Medulloblastoma-96): Long-Term Results from a Prospective, Multicentre Trial. The Lancet Oncology, 7, 813-820.
Del Charco, J.O., Bolek, T.W., McCollough, W.M., Maria, B.L., Kedar, A., Braylan, R.C., et al. (1998) Medulloblastoma: Time-Dose Relationship Based on a 30-Year Review. International Journal of Radiation Oncology, Biology, Physics, 42, 147-154.
Hughes, E.N., Shillito, J., Sallan, S.E., Loeffler, J.S., Cassady, J.R. and Tarbell, N.J. (1988) Medulloblastoma at the Joint Center for Radiation Therapy between 1968 and 1984. Cancer, 61, 1992-1998. https://doi.org/10.1002/1097-0142(19880515)61:10 3.0.CO;2-J
Nayil, K., Makhdoomi, R., Ramzan, A., Zahoor, S., Rasool, M., Wani, A., Dhar, A., Mubeen, B., Singh, S., Bhat, R. and Kirmani, A. (2011) Childhood Tumors of the Brain: Demographic Pattern over a Ten-Year Period in the Kashmir Valley. Pediatric Neurosurgery, 47, 31-37. https://doi.org/10.1159/000327143
Nasir, S., Jamila, B. and Khaleeq, S. (2010) A Retrospective Study of Primary Brain Tumors in Children under 14 Years of Age at PIMS, Islamabad. Asian Pacific Journal of Cancer Prevention, 11, 1225-1227.
Khalil, E.M. (2008) Treatment Results of Adults and Children with Medulloblastoma NCI, Cairo University Experience. Journal of the Egyptian National Cancer Institute, 20, 175-186.
El-Gaidi, M.A. (2011) Descriptive Epidemiology of Pediatric Intracranial Neoplasms in Egypt. Pediatric Neurosurgery, 47, 385-395. https://doi.org/10.1159/000337872
Treatment Outcome
Prognostic Factors
Rickert, C.H. and Paulus, W. (2001) Epidemiology of Central Nervous System Tumors in Childhood and Adolescence Based on the New WHO Classification. Child’s Nervous System, 17, 503-511. https://doi.org/10.1007/s003810100496
Lashley, P.M., Clarke, H. and Archer, E.Y. (1991) Primary Pediatric Brain Tumours in Barbados: 10-Year Analysis (1978-1988). Journal of Tropical Pediatrics, 37, 64-66. https://doi.org/10.1093/tropej/37.2.64
Olasode, B.J., Shokunbi, M.T. and Aghadiuno, P.U. (2000) Intracranial Neoplasms in Ibadan, Nigeria. East African Medical Journal, 77, 4-8.
Wilne, S., Collier, J., Kennedy, C., Koller, K., Grundy, R. and Walker, D. (2007) Presentation of Childhood CNS Tumours: A Systematic Review and Meta-Analysis. The Lancet Oncology, 8, 685-695.
Jenkin, D., Al Shabanah, M., Al Shail, E., Gray, A., Hassounah, M., Khafaga, Y., et al. (2000) Prognostic Factors for Medulloblastoma. International Journal of Radiation Oncology, Biology, Physics, 47, 573-584.
Zeltzer, P.M., Boyett, J.M., Finlay, J.L., et al. (1999) Metastasis Stage, Adjuvant Treatment, and Residual Tumor Are Prognostic Factors for Medulloblastoma in Children: Conclusions from the Children’s Cancer Group 921 Randomized Phase III Study. Journal of Clinical Oncology, 17, 832-834. https://doi.org/10.1200/JCO.1999.17.3.832
Packer, R.J., Rood, B.R. and MacDonald, T.J. (2003) Medulloblastoma: Present Concepts of Stratification into Risk Groups. Pediatric Neurosurgery, 39, 60-67. https://doi.org/10.1159/000071316
Labbe, D., Provencal, M., Lamy, S., et al. (2009) The Flavonols Quercetin, Kaempferol, and Myricetin Inhibit Hepatocyte Growth Factor-Induced Medulloblastoma Cell Migration. Journal of Nutrition, 139, 646-652. https://doi.org/10.3945/jn.108.102616
Yock, T.I., Friedman, H., Kun, L., Kepner, J., Barnes, P. and Tarbell, N.J. (2001) Response to Pre-Radiation Chemotherapy Is Predictive of Improved Survival in High Risk Medulloblastoma: Results from the Paediatric Oncology Group (POG 9031). International Journal of Radiation Oncology, Biology, Physics, 51, 120-121.
Bailey, C.C., Gnekow, A., Wellek, S., et al. (1995) Prospective Randomized Trial of Chemotherapy Given before Radiotherapy in Childhood MB. International Society of Pediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Medical and Pediatric Oncology, 25, 166-178. https://doi.org/10.1002/mpo.2950250303
Strother, D., Ashley, D., Kellie, S.J., et al. (2001) Feasibility of Four Consecutive High-Dose Chemotherapy Cycles with Stem-Cell Rescue for Patients with Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor after Craniospinal Radiotherapy: Results of a Collaborative Study. Journal of Clinical Oncology, 19, 2696-2704. https://doi.org/10.1200/JCO.2001.19.10.2696
Dhodapkar, K., Dunkel, I.J., Gardner, S., et al. (2002) Preliminary Results of Dose Intensive Pre-Irradiation Chemotherapy in Patients Older than 10 Years of Age with High Risk Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumors. Medical and Pediatric Oncology, 38, 47-48. https://doi.org/10.1002/mpo.1262
Merchant, T.E., Kun, L.E., Krasin, M.J., et al. (2008) Multi-Institution Prospective Trial of Reduced-Dose CSI (23.4 Gy) Followed by Conformal Posterior Fossa (36 Gy) and Primary Site Irradiation (55.8 Gy) and Dose-Intensive Chemotherapy for Average-Risk Medulloblastoma. International Journal of Radiation Oncology, Biology, Physics, 70, 782-787.
Thomas, P.R., Deutsch, M., Kepner, J.L., et al. (2000) Low-Stage Medulloblastoma: Final Analysis of Trial Comparing Standard-Dose with Reduced-Dose Neuraxis Irradiation. Journal of Clinical Oncology, 18, 3004-3011. https://doi.org/10.1200/JCO.2000.18.16.3004
Chi, S.N., Gardner, S.L., Levy, A.S., et al. (2004) Feasibility and Response to Induction Chemotherapy Intensified with High-Dose Methotrexate for Young Children with Newly Diagnosed High-Risk Disseminated Medulloblastoma. Journal of Clinical Oncology, 22, 4881-4887. https://doi.org/10.1200/JCO.2004.12.126
Rutkowski, S., Gerber, N.U., von, H.K., et al. (2009) Treatment of Early Childhood Medulloblastoma by Postoperative Chemotherapy and Deferred Radiotherapy. Neuro-Oncology, 11, 201-210. https://doi.org/10.1215/15228517-2008-084
Ashley, D.M., Merchant, T.E., Strother, D., et al. (2012) Induction Chemotherapy and Conformal Radiation Therapy for Very Young Children with Non-Metastatic Medulloblastoma: Children’s Oncology Group Study P9934. Journal of Clinical Oncology, 30, 3181-3186. https://doi.org/10.1200/JCO.2010.34.4341
Gajjar, A., Fouladi, M., Walter, A.W., et al. (1999) Comparison of Lumbar and Shunt Cerebrospinal Fluid Specimens for Cytologic Detection of Leptomeningeal Disease in Pediatric Patients with Brain Tumors. Journal of Clinical Oncology, 17, 1825-1828. https://doi.org/10.1200/JCO.1999.17.6.1825
Duffner, P.K., Horowitz, M.E., Krischer, J.P., et al. (1993) Postoperative Chemotherapy and Delayed Radiation in Children Less than Three Years of Age with Malignant Brain Tumors. The New England Journal of Medicine, 328, 1725-1731. https://doi.org/10.1056/NEJM199306173282401
Taylor, R.E., Bailey, C.C., Robinson, K.J., et al. (2005) Outcome for Patients with Metastatic (M2-3) Medulloblastoma Treated with SIOP/UKCCSG PNET-3 Chemotherapy. European Journal of Cancer, 41, 727-734.
Gandola, L., Massimino, M., Cefalo, G., et al. (2009) Hyperfractionated Accelerated Radiotherapy in the Milan Strategy for Metastatic Medulloblastoma. Journal of Clinical Oncology, 27, 566-571. https://doi.org/10.1200/JCO.2008.18.4176
Tarbell, N.J., Friedman, H., Polkinghorn, W.R., et al. (2013) High-Risk Medulloblastoma: A Pediatric Oncology Group Randomized Trial of Chemotherapy before or after Radiation Therapy (POG 9031). Journal of Clinical Oncology, 31, 2936-2941. https://doi.org/10.1200/JCO.2012.43.9984
Sirachainan, N., Nuchprayoon, I., Thanarattanakorn, P., et al. (2011) Outcome of Medulloblastoma in Children Treated with Reduced-Dose Radiation Therapy plus Adjuvant Chemotherapy. Journal of Clinical Neuroscience, 18, 515-519.
Weil, M.D., Lamborn, K., Edwards, M.S. and Wara, W.M. (1998) Influence of a Child’s Sex on Medulloblastoma Outcome. JAMA, 279, 1474-1476. https://doi.org/10.1001/jama.279.18.1474
Prados, M.D., Warnick, R.E., Wara, W.M., Larson, D.A., Lamborn, K. and Wilson, C.B. (1995) Medulloblastoma in Adults. International Journal of Radiation Oncology, Biology, Physics, 32, 1145-1152.